Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Christopher Kiff"'
Publikováno v:
PharmacoEconomics Open
Objective The aim of this study was to investigate the cost effectiveness of nivolumab versus docetaxel in previously treated, advanced non–small-cell lung cancer (NSCLC) in England and assess how conditional reimbursement within the Cancer Drugs F
Autor:
Robert Carroll, Christopher Kiff, Dara Stein, David Tyas, Delphine Saragoussi, Mira Soni, Ayman Nassar, Nick Maisey
Publikováno v:
Future oncology (London, England). 17(24)
Lay abstract This study looked at the characteristics and quality of life (QoL) of patients who were taking the drug, nivolumab, and how well it works for advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma. GEJ adenocarcinoma is a rare t
Publikováno v:
ClinicoEconomics and Outcomes Research. 11:309-324
Purpose: Cost-effectiveness analyses (CEA) of new technologies typically include “background” costs (eg, all “related” health care costs other than the specific technology under evaluation) as well as drug costs. In oncology, these are often
Autor:
Cynthia Macahilig, Alicia C. Shillington, Christopher Kiff, FE Cotte, V Dave, P Singh, M Contente
Publikováno v:
Value in Health. 23:S427
Autor:
D. Ntais, James W. Shaw, K. Noon, Christopher Kiff, Michael DeRosa, Kim Cocks, Madeleine King, Fiona Taylor, Bryan Bennett
Publikováno v:
Value in Health. 22:S922